Caris Life Sciences, Inc.

CAINASDAQHealthcare● Active

$16.69

+$0.20(+1.21%)

Market Cap$4.7B

P/E Ratio—

52W High$42.5

52W Low$14.19

Avg Volume2.6M

Open$17.43

Beta0.79

Earnings Financials Revenue

Caris Life Sciences, Inc. (CAI) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

CAI · earnings · updated Jun 8, 2026

Latest Earnings

Q2 FY2026Report Date: May 7, 2026

EPS Actual

$0.28

Est. -$0.02 · +1500.0%

Revenue

$0.29B

Est. $0.24B · +21.8%

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 7, 2026

After Market Close

▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak

CAI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.07

Rev. $15.39B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.07

Rev. Est.$15.39B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 11, 2026	$0.02	—	—	—	$0.24B	—
▲ Q2 FY2026	May 7, 2026	-$0.02	$0.28	+1500.0%	$0.29B	$0.24B	+21.8%
▲ Q2 FY2026	May 7, 2026	-$0.02	-$0.00	+92.5%	$0.22B	$0.21B	+3.2%
▲ Q4 FY2025	Nov 5, 2025	-$0.08	$0.08	+200.0%	$0.22B	$0.28B	-22.8%
▼ Q3 FY2025	Aug 12, 2025	-$0.21	-$0.54	-157.1%	$0.18B	$0.14B	+31.8%

Q3 FY2026

Aug 11, 2026

EPS Actual

—

EPS Est.

$0.02

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 7, 2026Beat

EPS Actual

$0.28

EPS Est.

-$0.02

EPS Surpr.

+1500.0%

Revenue

$0.29B

Q2 FY2026

May 7, 2026Beat

EPS Actual

-$0.00

EPS Est.

-$0.02

EPS Surpr.

+92.5%

Revenue

$0.22B

Q4 FY2025

Nov 5, 2025Beat

EPS Actual

$0.08

EPS Est.

-$0.08

EPS Surpr.

+200.0%

Revenue

$0.22B

Q3 FY2025

Aug 12, 2025Miss

EPS Actual

-$0.54

EPS Est.

-$0.21

EPS Surpr.

-157.1%

Revenue

$0.18B

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$0.14	$0.14	$0.15	3
Q3 FY2028	$0.13	$0.14	$0.14	3
Q2 FY2028	$0.12	$0.12	$0.12	3
Q1 FY2028	$0.11	$0.11	$0.11	3
Q4 FY2027	$0.11	$0.11	$0.12	2
Q3 FY2027	$0.10	$0.10	$0.10	2

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$0.3B	$0.4B	$0.4B	4
Q3 FY2028	$0.3B	$0.3B	$0.3B	4
Q2 FY2028	$0.3B	$0.3B	$0.3B	5
Q1 FY2028	$0.3B	$0.3B	$0.3B	2
Q4 FY2027	$0.3B	$0.3B	$0.3B	3
Q3 FY2027	$0.3B	$0.3B	$0.3B	3

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q2 FY2026	May 7, 2026	+1500.0%	$19.13	$19.84	+3.71%
▲ Q2 FY2026	May 7, 2026	+92.5%	$19.13	$19.84	+3.71%
▲ Q4 FY2025	Nov 5, 2025	+200.0%	$31.18	$29.21	-6.32%
▼ Q3 FY2025	Aug 12, 2025	-157.1%	$30.21	$32.46	+7.45%

Q2 FY2026+3.71%

Report Date

May 7, 2026

EPS Beat/Miss

+1500.0%

Price Before

$19.13

Price After

$19.84

Q2 FY2026+3.71%

Report Date

May 7, 2026

EPS Beat/Miss

+92.5%

Price Before

$19.13

Price After

$19.84

Q4 FY2025-6.32%

Report Date

Nov 5, 2025

EPS Beat/Miss

+200.0%

Price Before

$31.18

Price After

$29.21

Q3 FY2025+7.45%

Report Date

Aug 12, 2025

EPS Beat/Miss

-157.1%

Price Before

$30.21

Price After

$32.46

Avg Beat Reaction+0.37%

Avg Miss Reaction+7.45%

Beat Rate3 / 4 quarters

Largest Move+7.45% (Q3 FY2025)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Caris Life Sciences, Inc. (CAI) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.28 — beating the analyst consensus of $-0.02 by +1500.0%. CAI has beaten EPS estimates for 3 consecutive quarters. The next CAI earnings date is expected around September 1, 2026.

Each quarter, investors track CAI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CAI revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

CAI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

CAI earnings · 5 questions

Caris Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. CAI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CAI historically reports after market close (AMC).

CAI earnings datewhen is CAI earningsCAI next earnings datewhen does CAI report earningsCAI earnings calendar

▸ Source: FMP · Caris Life Sciences, Inc. SEC filings · US GAAP · Caris Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026